Abbott is recalling a communication system that monitors heart failure patients implanted with its Heartmate 3 left ventricular assist device (LVAD) due to a risk that the system could unexpectedly ...
SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...
ST. PAUL, Minn.-- (BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the company has received an Innovation Award for its HeartMate 3 ™ Left ...
Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3
ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...
ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ heart pump ...
When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...
MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...
ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Three US centers report increasing rates ...
Washington, DC - Data from 64 HeartMate II (Thoratec) left ventricular assist device (LVAD) patients treated at the Henry Ford Hospital in Detroit suggest that many of the patients implanted with the ...
The FDA approved a new, less invasive surgical technique for the placement of Abbott’s best-selling heart pump, allowing patients to avoid open surgery. The HeartMate 3 left ventricular assist device ...
In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback